The HDAC4 NM_001378414.1:c.1426C>T (NP_001365343.1:p.(Pro476Ser)) missense variant has not previously been reported in somatic cancers (COSMIC). Based on available guidelines, this variant is considered to be a Variant of Uncertain Significance (VUS).
Five-step scale from benign to pathogenic. This variant is uncertain. Select a step to read what it means.
This variantScenario
BenignPathogenic
Uncertain.The recorded classification is uncertain significance.
In plain language
Gene-level background from the recorded interpretation.
Words with a dotted underline have a short definition. Hover or tap them.
About HDAC4
HDAC4 encodes a class IIa histone deacetylase that helps regulate gene activity by altering chromatin structure and the function of other proteins, including factors involved in development, cell-cycle control, and DNA-damage responses. It has been implicated in cancer biology rather than a single defining inherited disorder, with context-dependent roles as either an oncogene or tumor suppressor. HDAC4 deletions have been reported in melanoma, while increased expression has been associated with gastric cancer and acute lymphoblastic leukemia.
LYFE Sciences is an AI system, and it can make mistakes.
Criteria may be applied incorrectly, sources may be misread, and a
confident-looking classification can still be wrong.
Double-check every criterion and its underlying evidence
before relying on any call.
01The reasoning
How it was classified
The recorded framework is Generic ACMG/AMP 2015 with ClinGen SVI recommendations. The criteria and strengths shown below come from the saved assessment; this page does not recalculate the classification.
Recorded applied criteria
The applied criteria and their strengths are shown as assessed under the stated framework.
Met at supporting strength: gnomAD v4.1 grpmax FAF is 8.78e-06, below the <=0.0001 PM2 threshold.
PP3Supporting
PP3 · supporting
Met at supporting strength: REVEL 0.718 meets the generic PP3 supporting threshold of >=0.644 for this missense variant.
Benign criteria applied · 0
No benign criterion marked as applied in the recorded assessment.
Recorded classification: Uncertain significance
VUS: PM2 (supporting) and PP3 (supporting) provide two supporting criteria, insufficient for any ACMG/AMP pathogenic or benign combination rule.
02The sources
Evidence at a glance
Evidence summaries and captured source records, where available. Missing entries should not be interpreted as negative findings.
gnomAD v4.1
gnomAD v2.1
Population frequency
18 / 1,613,682 alleles
gnomAD v4.1: 18 / 1,613,682 alleles. Recorded AF 1.11546e-05. Recorded homozygote count 0.
gnomAD v2.1
This variant is present in gnomAD v2.1 (AF= 8.01186e-06; MAF= 0.00080%, 2/249630 alleles, homozygotes = 0) and has highest observed frequency in the European (non-Finnish) population (AF= 1.77434e-05; MAF= 0.00177%, 2/112718 alleles, homozygotes = 0); grpmax FAF= 2.95e-06.
ACMG/AMP criteria under Generic ACMG/AMP 2015 with ClinGen SVI recommendations, with the data and sources behind each one.
28 criteria with recorded statuses: 2 met · 7 not met · 15 not assessed · 4 not applicable. Open any row for the full reasoning, the rule and the evidence behind it.
PS2, PM6, PP1, and BS4 are not assessed because the available evidence contains no proband de novo documentation, parental testing, family pedigree, affected-relative phenotypes, or familial segregation results.
PS3 and BS3 are both not_assessed because the available case evidence contains no variant-specific functional assay result for NM_001378414.1:c.1426C>T (p.Pro476Ser).
The available literature pass contains zero PMIDs and paper_extracts.json is empty, so no publication-based functional finding can be cited for these criteria.
Human review is required to determine whether additional variant-specific functional evidence exists outside the available case evidence.
PS4, PP4, and BP5 are not assessed because the required case-control or patient-level clinical evidence is absent.
PP5 and BP6 are not met because the exact variant is absent from ClinVar and no expert-panel classification is available.
Generic ACMG/AMP rules govern because no VCEP covers HDAC4.
The missense consequence selects the REVEL path exclusively; SpliceAI and BayesDel are not counted for PP3 or BP4.
Population evidence supports PM2 at supporting strength because the variant's filtering allele frequency is below 0.0001.
BA1 and BS1 are not met because the relevant grpmax FAF values are far below their generic thresholds.
BS2 is not assessed because no documented healthy-adult observation, inheritance model, or early-onset full-penetrance context is available.
No criteria match.
Met · 2
PM2SupportingACMGMet at supporting strength: gnomAD v4.1 grpmax FAF is 8.78e-06, below the <=0.0001 PM2 threshold.
Details ▾Hide ▴
Reasoning
PM2 is met at supporting strength under the supplied generic threshold. The variant is present but extremely rare in the default all-comers population datasets: gnomAD v4.1 has total AF=1.11546e-05 and grpmax FAF=8.78e-06, while gnomAD v2.1 has total AF=8.01186e-06 and grpmax FAF=2.95e-06. Each is below the <=0.0001 PM2 threshold. The supplemental non-cancer subsets are also rare (v2.1 exomes AF=4.24708e-06; v3.1 genomes AF=2.02703e-05 with grpmax FAF=1.171e-05), but generic rules do not require substituting those subsets for the default all-comers sources.
Rule
PM2 (supporting): <= 0.0001 — SVI recommendation to downgrade PM2 to Supporting (ClinGen SVI 2020) (PMID:25741868)
Evidence considered
gnomAD v4.1 all-comers data: total AF=1.11546e-05 from 18/1,613,682 alleles, homozygotes=0, grpmax FAF=8.78e-06.
gnomAD v2.1 all-comers data: total AF=8.01186e-06 from 2/249,630 exome alleles, homozygotes=0, grpmax FAF=2.95e-06.
The supplied generic PM2 supporting threshold is <=0.0001; the variant is not absent, so the extremely-low-frequency threshold is applied.
The available non-cancer subsets are concordantly rare: gnomAD v2.1 non-cancer exomes AF=4.24708e-06 and gnomAD v3.1 non-cancer genomes AF=2.02703e-05 with grpmax FAF=1.171e-05.
PP3SupportingACMG_2015Met at supporting strength: REVEL 0.718 meets the generic PP3 supporting threshold of >=0.644 for this missense variant.
Details ▾Hide ▴
Reasoning
The variant is a missense substitution, NM_001378414.1:c.1426C>T (p.Pro476Ser), so the generic PP3/BP4 missense path applies and REVEL is the sole applicable predictor; SpliceAI is not used for this path. REVEL is 0.718, which meets the published generic PP3 supporting threshold of >=0.644 from the ClinGen SVI REVEL calibration (Pejaver et al. 2022, PMID:36413997). BayesDel is not used because no generic ACMG-strength calibration is established.
Rule
Multiple lines of computational evidence support a deleterious effect on the gene or gene product (conservation, evolutionary, splicing impact, etc.).
Evidence considered
Variant consequence: missense, NM_001378414.1:c.1426C>T, NP_001365343.1:p.(Pro476Ser), in exon 12.
Applicable computational path: REVEL only for a missense variant; the SpliceAI result is not counted for PP3/BP4 on this path.
Local REVEL lookup: score 0.718.
ClinGen SVI REVEL calibration (Pejaver et al. 2022, Am J Hum Genet; PMID:36413997): generic PP3 supporting threshold >=0.644; REVEL 0.718 meets it.
BayesDel score 0.183125 is not used because no generic ACMG-strength calibration is established.
Sources
revel
Not met · 7 · evaluated, threshold not reached
PS1ACMG_2015Not met: no established pathogenic HDAC4 variant causing p.Pro476Ser was identified, and the variant is absent from ClinVar.
Details ▾Hide ▴
Reasoning
The variant is HDAC4 p.Pro476Ser (NM_001378414.1:c.1426C>T). The case evidence identifies no established pathogenic HDAC4 variant producing the same amino-acid change, and ClinVar is absent for the variant. Therefore, the same-amino-acid requirement for PS1 is not met. No splice-impact concern changes this conclusion because SpliceAI's maximum delta score is 0.001.
Rule
Same amino acid change as a previously established pathogenic variant regardless of nucleotide change. ... Caveat: Beware of changes that impact splicing rather than at the amino acid/protein level.
ClinVar status: variant absent; no ClinVar variation ID or classification was reported.
SpliceAI maximum delta score = 0.001, with no significant predicted splice impact.
Sources
generic_acmg_combination_rules
PM5ACMG_2015Not met: zero qualifying pathogenic alternate missense variants at HDAC4 residue 476 were identified for comparison with p.Pro476Ser.
Details ▾Hide ▴
Reasoning
The variant is HDAC4 p.Pro476Ser. The case evidence contains no confirmed pathogenic or likely pathogenic HDAC4 missense comparator at residue 476: the PM5 candidate set has zero candidates, and ClinVar is absent for the current variant. No qualifying alternate missense change at the same amino-acid residue was identified, so PM5 is not met. The variant is a missense substitution rather than a splice-altering consequence; SpliceAI maximum delta is 0.001.
Rule
Novel missense change at an amino acid residue where a different missense change determined to be pathogenic has been seen before. ... Caveat: Beware of changes that impact splicing rather than at the amino acid/protein level.
Evidence considered
PM5 comparator collection: same_residue_candidates = 0 and total_candidates_seen = 0.
SpliceAI maximum delta score = 0.001, with no significant predicted splice impact.
Sources
pm5_candidatesgeneric_acmg_combination_rules
PP5ACMG_2015Not met: ClinVar has no exact-variant record, with 0 submissions and 0 expert-panel submissions supporting pathogenicity.
Details ▾Hide ▴
Reasoning
PP5 is not met because the exact variant is absent from the ClinVar record and the submission audit reports zero submissions and zero expert-panel submissions. No reputable exact-variant pathogenic or likely pathogenic assertion is available.
Rule
Reputable source recently reports variant as pathogenic, but the evidence is not available to the laboratory to perform an independent evaluation.
Evidence considered
ClinVar exact-match resolution reports status absent for NM_001378414.1:c.1426C>T, with submissions_total=0 and expert_panel_submissions=0.
No reputable exact-variant Pathogenic or Likely pathogenic assertion was identified.
BA1ACMGNot met: gnomAD v4.1 grpmax FAF is 8.78e-06 (0.000878%), below the >=0.05 BA1 threshold.
Details ▾Hide ▴
Reasoning
BA1 is not met. The governing generic stand-alone threshold is >=0.05, and the appropriate filtering frequency is the gnomAD v4.1 grpmax FAF of 8.78e-06 (0.000878%), far below 0.05. gnomAD v2.1 also has a grpmax FAF of 2.95e-06. The observed popmax point estimate is not used for this decision, and no frequency-based BA1 call is justified.
BS1ACMGNot met: gnomAD v4.1 grpmax FAF is 8.78e-06, far below the generic BS1 default threshold of >=0.01.
Details ▾Hide ▴
Reasoning
BS1 is not met on the available population data. The generic default threshold is >=0.01, but the required filtering frequency is only 8.78e-06 in gnomAD v4.1 and 2.95e-06 in gnomAD v2.1, both far below 0.01. No maximum-credible-frequency calculation is needed because the observed filtering frequencies are already orders of magnitude below the default BS1 threshold.
Rule
BS1 (strong): >= 0.01 — Generic SVI default; per-gene derivation preferred (Whiffin et al. 2017) (PMID:28518168)
Evidence considered
gnomAD v4.1 all-comers data: grpmax FAF=8.78e-06; total AF=1.11546e-05 from 18/1,613,682 alleles.
gnomAD v2.1 all-comers data: grpmax FAF=2.95e-06; total AF=8.01186e-06 from 2/249,630 exome alleles.
The generic BS1 threshold is >=0.01. The FAF values, rather than popmax point estimates, are used for this assessment.
BP4ACMG_2015Not met: REVEL 0.718 exceeds the generic BP4 supporting threshold of <=0.29, so the missense result is indeterminate for benign computational evidence.
Details ▾Hide ▴
Reasoning
The variant is a missense substitution, NM_001378414.1:c.1426C>T (p.Pro476Ser), so the generic BP4 missense path applies and REVEL is the sole applicable predictor; SpliceAI is not used for this path. REVEL is 0.718, which is above the generic BP4 supporting threshold of <=0.29 and therefore lies outside the benign-supporting range; the gray-zone REVEL result does not permit substituting the SpliceAI score. BayesDel is not used because no generic ACMG-strength calibration is established.
Rule
Multiple lines of computational evidence suggest no impact on gene or gene product (conservation, evolutionary, splicing impact, etc)
Evidence considered
Variant consequence: missense, NM_001378414.1:c.1426C>T, NP_001365343.1:p.(Pro476Ser), in exon 12.
Applicable computational path: REVEL only for a missense variant; the SpliceAI result is not counted for PP3/BP4 on this path.
Local REVEL lookup: score 0.718.
ClinGen SVI REVEL calibration (Pejaver et al. 2022, Am J Hum Genet; PMID:36413997): generic BP4 supporting threshold <=0.29; REVEL 0.718 does not meet it and is gray-zone for BP4.
BayesDel score 0.183125 is not used because no generic ACMG-strength calibration is established.
Sources
revel
BP6ACMG_2015Not met: ClinVar has no exact-variant record, with 0 submissions and 0 expert-panel submissions supporting benignity.
Details ▾Hide ▴
Reasoning
BP6 is not met because the exact variant is absent from the ClinVar record and the submission audit reports zero submissions and zero expert-panel submissions. No reputable exact-variant benign or likely benign assertion is available.
Rule
Reputable source recently reports variant as benign, but the evidence is not available to the laboratory to perform an independent evaluation.
Evidence considered
ClinVar exact-match resolution reports status absent for NM_001378414.1:c.1426C>T, with submissions_total=0 and expert_panel_submissions=0.
No reputable exact-variant Benign or Likely benign assertion was identified.
Not assessed · 15 · no assessment recorded
PS2ACMG_2015Not assessed: no documented proband phenotype, family-history assessment, or confirmed maternity and paternity with both parents testing negative.
Details ▾Hide ▴
Reasoning
PS2 is not assessed. The available case evidence does not document a patient phenotype, absence of family history, or molecular confirmation of both maternity and paternity with the variant absent in both parents. Without those data, a confirmed de novo event cannot be established.
Rule
De novo (both maternity and paternity confirmed) in a patient with the disease and no family history.
Evidence considered
The case evidence contains no documented proband segregation or de novo-testing result, and no parental maternity or paternity confirmation.
Still missing
Document the proband's disease phenotype and family history.
Obtain variant testing results for both biological parents and confirmation of maternity and paternity.
PS3ACMG_2015Not assessed: no variant-specific validated in vitro or in vivo functional assay result is available for NM_001378414.1:c.1426C>T.
Details ▾Hide ▴
Reasoning
No variant-specific in vitro or in vivo functional assay result for NM_001378414.1:c.1426C>T (p.Pro476Ser) is present in the available case evidence. The available literature pass contains zero PMIDs, paper_extracts.json is empty, and no validated assay data, assay controls, reproducibility information, or calibrated strength assignment is available. Therefore, the evidence is insufficient to determine whether a well-established functional study supports a damaging effect or to assign PS3 strength.
Rule
Well-established in vitro or in vivo functional studies supportive of a damaging effect on the gene or gene product.
Evidence considered
The available literature pass contains zero PMIDs for this case.
paper_extracts.json is empty, so no extracted paper finding documents a functional assay for NM_001378414.1:c.1426C>T (p.Pro476Ser).
The available case evidence contains no variant-specific assay result, assay control data, reproducibility data, or clinical laboratory validation data for this variant.
Still missing
Variant-specific functional assay data for p.Pro476Ser, including assay controls and biological relevance, are unavailable.
No reproducibility or clinical diagnostic laboratory validation information is available.
No calibrated PS3 strength assignment is available.
PS4ACMG_2015Not assessed: gnomAD v4.1 shows 18/1,613,682 alleles, but no affected-case frequency, control comparison, OR/RR, or 95% CI is available.
Details ▾Hide ▴
Reasoning
PS4 cannot be assessed because no affected-case carrier count or frequency, matched control comparison, odds ratio, relative risk, or confidence interval was identified. The variant is present in gnomAD v4.1 at 18/1,613,682 alleles (AF 1.11546e-05), including 17/1,179,938 NFE alleles, but this population frequency alone is not a case-control comparison and does not provide the affected-individual prevalence required for PS4. The literature packet contains zero PMIDs and no PS4-classified papers to verify.
Rule
The prevalence of the variant in affected individuals is significantly increased compared to the prevalence in controls. ... Note 1: Relative risk (RR) or odds ratio (OR), as obtained from case-control studies, is >5.0 and the confidence interval around the estimate of RR or OR does not include 1.0.
Evidence considered
gnomAD v4.1 reports the exact variant at 18/1,613,682 total alleles (AF=1.11546e-05), with 17/1,179,938 European non-Finnish alleles (AF=1.44075e-05).
No affected-case carrier count, control comparison, OR/RR, or 95% CI is present; therefore no inequality against the PS4 OR/RR threshold can be written and no PS4 conclusion is made.
literature_pass.json reports total_pmids=0, so there were no packet.ai_classified_papers or PS4 papers requiring abstract/full-text verification.
Still missing
Affected-case carrier counts or frequency for NM_001378414.1:c.1426C>T
Matched control counts or frequency and a calculable OR/RR with 95% CI
A case-control paper or full-text report describing this exact variant in affected individuals
PM1ACMG_2015Not assessed: no complete HDAC4 domain assessment establishes that p.Pro476 lies in a critical domain without benign variation.
Details ▾Hide ▴
Reasoning
HDAC4 has no VCEP specification and vcep_materials.json contains no domain-table entry. The case documents no statistically significant hotspot, but it does not provide a complete, authoritative assessment of all established HDAC4 functional domains or whether those domains lack benign variation. The available literature title identifies a conserved 14-3-3 binding site in HDAC4, but does not establish that p.Pro476 lies within that site or satisfy the complete PM1 requirement. A definitive PM1 decision therefore cannot be made from the supplied evidence.
Rule
Located in a mutational hot spot and/or critical and well-established functional domain (e.g. active site of an enzyme) without benign variation.
Evidence considered
Cancer Hotspots result for HDAC4 P476: no result; the variant does not lie in a statistically significant hotspot.
PMID:33537682 title: 'Missense substitutions at a conserved 14-3-3 binding site in HDAC4 cause a novel intellectual disability syndrome.' The available abstract extraction does not map p.Pro476 to that site or document absence of benign variation.
vcep_materials.json: no HDAC4 VCEP and domain_tables is empty.
Still missing
A complete, residue-mapped HDAC4 functional-domain assessment with benign-variation review is unavailable.
PM3ACMG_2015Not assessed: no documented recessive disease context or parent/offspring phase result establishes this variant in trans with a pathogenic variant.
Details ▾Hide ▴
Reasoning
The case evidence does not document that NM_001378414.1:c.1426C>T (NP_001365343.1:p.(Pro476Ser)) occurs in an affected proband with a pathogenic variant in trans, and it does not establish a recessive HDAC4 disorder or provide parent/offspring testing for phase. Therefore, the recessive allelic requirement for PM3 cannot be assessed.
Rule
PM3: For recessive disorders, detected in trans with a pathogenic variant
Evidence considered
The case evidence contains no documented affected-proband allelic observation, pathogenic partner variant, or parent/offspring phase result for NM_001378414.1:c.1426C>T.
The case summary provides no inheritance assignment for the relevant HDAC4 disorder.
Still missing
Documented inheritance mode for the relevant HDAC4 disorder
Affected-proband observation with a second pathogenic variant
Parent or offspring testing establishing trans phase
PM6ACMG_2015Not assessed: no affected-proband de novo observation or parental testing showing the variant absent without confirmed maternity and paternity.
Details ▾Hide ▴
Reasoning
PM6 is not assessed. The available case evidence does not document an assumed de novo variant in an affected patient or testing showing the variant absent in the parents. No parental testing or family-history information is available to support this criterion.
Rule
Assumed de novo, but without confirmation of paternity and maternity.
Evidence considered
The case evidence contains no parental testing results, de novo assertion, or proband phenotype information relevant to PM6.
Still missing
Document the proband's disease phenotype and family history.
Document parental testing showing the variant absent in both parents, while distinguishing unconfirmed parentage from confirmed maternity and paternity.
PP1ACMG_2015Not assessed: no affected relatives or family variant testing are documented, so co-segregation and informative meioses cannot be evaluated.
Details ▾Hide ▴
Reasoning
PP1 is not assessed. The available case evidence contains no affected family members, variant testing across relatives, or meiosis/segregation observations. Therefore, co-segregation cannot be evaluated.
Rule
Co-segregation with disease in multiple affected family members in a gene definitively known to cause the disease.
Evidence considered
The case evidence contains no family pedigree, affected-relative phenotype data, familial variant testing, or segregation results.
Still missing
Identify affected relatives and document phenotype consistency.
Obtain variant testing and relationship information for informative family members to evaluate segregation across meioses.
PP2ACMG_2015Not assessed: the individual allele frequency is 1.11546e-05, but gene-wide benign-missense constraint and mechanism prevalence are unestablished.
Details ▾Hide ▴
Reasoning
The available case evidence is insufficient to establish both PP2 conditions for HDAC4: a low rate of benign missense variation across the gene and missense variants as a common disease mechanism. The case documents a germline HDAC4 missense-disease publication and a low frequency for this individual variant in gnomAD v4.1 (AF 1.11546e-05), but neither establishes gene-wide benign missense constraint or the required mechanism prevalence. PP2 therefore cannot be adjudicated from the supplied evidence.
Rule
Missense variant in a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease.
Evidence considered
gnomAD v4.1: the individual variant has AF = 1.11546e-05 (18/1,613,682 alleles; homozygotes = 0). This is not a gene-wide benign-missense rate.
PMID:33537682 concerns HDAC4 missense substitutions and a novel intellectual disability syndrome, but the available extraction does not quantify the gene's missense disease mechanism or benign missense rate.
Still missing
Gene-level benign missense constraint and evidence that missense is a common HDAC4 disease mechanism are unavailable.
PP4ACMG_2015Not assessed: no patient phenotype, family history, or disease-specific clinical description is available to evaluate PP4.
Details ▾Hide ▴
Reasoning
PP4 cannot be assessed because the case materials provide no patient phenotype or family history and no documented disease diagnosis to evaluate for high specificity to a single genetic etiology.
Rule
Patient’s phenotype or family history is highly specific for a disease with a single genetic etiology.
Evidence considered
The case evidence contains no patient phenotype, family history, or clinical diagnosis applicable to PP4.
Still missing
Patient phenotype and family history
Confirmed clinical diagnosis and disease-specific features
Evidence that the phenotype is highly specific for a disease with a single genetic etiology
BS2ACMG_2015Not assessed: no documented healthy adult carrying the variant and no inheritance or early-onset full-penetrance context is available.
Details ▾Hide ▴
Reasoning
BS2 cannot be assessed from the available evidence. gnomAD reports zero homozygotes in v2.1 and v4.1, but the case does not establish the disorder's inheritance, expected age-related penetrance, or observation of this variant in a documented healthy adult. Absence of homozygotes in population data is not the BS2 observation required by the rule.
Rule
BS2
Evidence considered
gnomAD v4.1 reports homozygotes=0, but does not provide a documented healthy-adult phenotype observation for this variant.
gnomAD v2.1 reports homozygotes=0, but does not provide a documented healthy-adult phenotype observation for this variant.
The case evidence does not establish an inheritance model or that full penetrance is expected at an early age.
Still missing
Documented healthy-adult carrier observation is unavailable.
Inheritance model and whether full penetrance is expected at an early age are unavailable.
BS3ACMG_2015Not assessed: no variant-specific validated functional result shows that NM_001378414.1:c.1426C>T has no damaging effect.
Details ▾Hide ▴
Reasoning
No variant-specific in vitro or in vivo functional assay result for NM_001378414.1:c.1426C>T (p.Pro476Ser) is present in the available case evidence. The available literature pass contains zero PMIDs, paper_extracts.json is empty, and no validated assay data, assay controls, reproducibility information, or calibrated strength assignment is available. Therefore, the evidence is insufficient to determine whether a well-established functional study shows no damaging effect on protein function or splicing or to assign BS3 strength.
Rule
Well-established in vitro or in vivo functional studies show no damaging effect on protein function or splicing.
Evidence considered
The available literature pass contains zero PMIDs for this case.
paper_extracts.json is empty, so no extracted paper finding documents a functional assay for NM_001378414.1:c.1426C>T (p.Pro476Ser).
The available case evidence contains no variant-specific assay result, assay control data, reproducibility data, or clinical laboratory validation data for this variant.
Still missing
Variant-specific functional assay data for p.Pro476Ser, including assay controls and biological relevance, are unavailable.
No reproducibility or clinical diagnostic laboratory validation information is available.
No calibrated BS3 strength assignment is available.
BS4ACMG_2015Not assessed: no tested affected relatives are documented, so lack of segregation and possible phenocopies cannot be evaluated.
Details ▾Hide ▴
Reasoning
BS4 is not assessed. The available case evidence does not identify affected family members who were tested for the variant, so lack of segregation cannot be demonstrated. The phenocopy caveat also cannot be evaluated without family phenotypes and molecular results.
Rule
Lack of segregation in affected members of a family.
Evidence considered
The case evidence contains no affected-relative testing or family phenotype data demonstrating that the variant fails to segregate with disease.
Still missing
Document affected relatives, their phenotypes, and variant test results.
Assess whether any apparently discordant affected relatives could represent phenocopies or another pathogenic variant.
BP1ACMG_2015Not assessed: HDAC4 truncating/deletion disease and a missense disorder are documented, but predominance of truncating disease variants is unestablished.
Details ▾Hide ▴
Reasoning
The variant is missense, so BP1 is applicable in principle. The case contains evidence that HDAC4 haploinsufficiency and deletions are disease-associated and also identifies a published HDAC4 missense disorder, but it does not establish that HDAC4 disease is primarily caused by truncating variants rather than missense or other mechanisms. The required gene-level predominance cannot be determined from the supplied evidence.
Rule
Missense variant in a gene for which primarily truncating variants are known to cause disease.
Evidence considered
PMID:20691407 is titled 'Haploinsufficiency of HDAC4 causes brachydactyly mental retardation syndrome'; this supports a loss-of-function/deletion disease mechanism but does not establish that truncating variants are the primary mechanism for all HDAC4 disease.
PMID:33537682 is titled 'Missense substitutions at a conserved 14-3-3 binding site in HDAC4 cause a novel intellectual disability syndrome'; this demonstrates reported missense disease but does not quantify mechanism predominance.
Still missing
A comprehensive HDAC4 disease-variant spectrum establishing that truncating variants are the primary disease mechanism is unavailable.
BP2ACMG_2015Not assessed: no documented phase result shows this variant in trans or cis with a pathogenic variant in an affected individual.
Details ▾Hide ▴
Reasoning
The case evidence does not document NM_001378414.1:c.1426C>T in trans with a pathogenic variant in an affected individual with a fully penetrant dominant disorder, or in cis with a pathogenic variant in any inheritance pattern. No parent/offspring or other phase data are available, so BP2 cannot be assessed.
Rule
BP2: Observed in trans with a pathogenic variant for a fully penetrant dominant gene/disorder or observed in cis with a pathogenic variant in any inheritance pattern.
Evidence considered
The case evidence contains no documented affected-proband observation, pathogenic partner variant, or molecular/family phase result establishing cis or trans phase for NM_001378414.1:c.1426C>T.
Still missing
Affected-proband observation with a pathogenic partner variant
Parent, offspring, or molecular phasing data establishing cis or trans phase
Evidence that any dominant disorder involved is fully penetrant, if the trans path is considered
BP5ACMG_2015Not assessed: no case-level evidence shows that the variant occurred with an alternate molecular basis for the disease.
Details ▾Hide ▴
Reasoning
BP5 cannot be assessed because the case materials do not document that this variant was found in a case with an alternate molecular basis for disease. No patient-level diagnostic result or alternate molecular cause is available.
Rule
Variant found in a case with an alternate molecular basis for disease.
Evidence considered
No case-level phenotype, molecular diagnosis, or alternate molecular basis is documented for this variant.
Still missing
A case containing the exact variant
An independently established alternate molecular basis for that case's disease
Not applicable · 4· recorded as not applicableShow reasons ▾Hide reasons ▴PVS1N/ANot applicable: PVS1 requires a null variant (nonsense, frameshift, canonical splice, start-loss or stop-loss), and this is a missense variant.
Details ▾Hide ▴
Reasoning
PVS1 (ClinGen SVI PVS1 recommendations, PMC6185798, pvs1_generic_framework) applies only to null variant classes — nonsense, frameshift, canonical ±1/2 splice-consensus, translation-initiation-codon loss, and stop-loss variants — each expected to trigger nonsense-mediated decay or otherwise abolish normal protein function. NM_001378414.1:c.1426C>T in HDAC4 is a missense substitution predicted to produce NP_001365343.1:p.(Pro476Ser). As a result, no null-variant mechanism (nonsense-mediated decay, truncation, or canonical splice disruption) is triggered by this variant class, so PVS1's structural prerequisite is not met by this variant class. No VCEP criteria specification covers PVS1 for HDAC4, so the generic ACMG/AMP 2015 definition applies. This determination was made deterministically from the variant's consequence class, prior to LLM adjudication.
PM4N/ANot applicable: PM4 requires a protein-length change, and this is a missense variant.
Details ▾Hide ▴
Reasoning
PM4 (Richards et al. 2015, PMID:25741868) applies to protein length changes: in-frame insertions/deletions in a non-repetitive region, or stop-loss variants that extend the protein past the reference stop codon. NM_001378414.1:c.1426C>T in HDAC4 is a missense substitution predicted to produce NP_001365343.1:p.(Pro476Ser). As a result, no change in protein length occurs, so there is nothing for this criterion to evaluate, so PM4's structural prerequisite is not met by this variant class. No VCEP criteria specification covers PM4 for HDAC4, so the generic ACMG/AMP 2015 definition applies. This determination was made deterministically from the variant's consequence class, prior to LLM adjudication.
BP3N/ANot applicable: BP3 requires an in-frame indel in a repeat region, and this is a missense variant.
Details ▾Hide ▴
Reasoning
BP3 (Richards et al. 2015, PMID:25741868) applies to in-frame insertions/deletions located in a repetitive region without a known function. NM_001378414.1:c.1426C>T in HDAC4 is a missense substitution predicted to produce NP_001365343.1:p.(Pro476Ser). As a result, the variant does not alter protein length within a repeat region, so there is nothing for this criterion to evaluate, so BP3's structural prerequisite is not met by this variant class. No VCEP criteria specification covers BP3 for HDAC4, so the generic ACMG/AMP 2015 definition applies. This determination was made deterministically from the variant's consequence class, prior to LLM adjudication.
BP7N/ANot applicable: BP7 requires a synonymous variant, and this is a missense variant.
Details ▾Hide ▴
Reasoning
BP7 (Richards et al. 2015, PMID:25741868) is defined for a synonymous (silent) variant for which splicing prediction algorithms predict no impact to the splice consensus sequence and the nucleotide is not highly conserved. NM_001378414.1:c.1426C>T in HDAC4 is a missense substitution predicted to produce NP_001365343.1:p.(Pro476Ser). As a result, the encoded protein sequence is altered, so the criterion's silent-variant premise does not hold regardless of any splicing prediction, so BP7's structural prerequisite is not met by this variant class. No VCEP criteria specification covers BP7 for HDAC4, so the generic ACMG/AMP 2015 definition applies. This determination was made deterministically from the variant's consequence class, prior to LLM adjudication.
Rule
deterministic_prefilter: requires_synonymous
Evidence considered
Deterministic consequence classification: missense (prefetch.json normalized protein consequence)
VCEP criterion policy: absent
Sources
generic_acmg_combination_rules
Identifiers
Gene
HDAC4
Transcript
NM_001378414.1
Coding (HGVS c.)
NM_001378414.1:c.1426C>T
Protein (HGVS p.)
NP_001365343.1:p.(Pro476Ser)
GRCh38
chr2:239126563 G>A
GRCh37
chr2:240048259 G>A
Location and type
Exon 12 · missense
Gene diagram
Every interpreted variant in HDAC4, mapped onto the exon structure of NM_001378414.1. Select a row to find it on the plot.
HDAC4NM_001378414.1
Fetching transcript structure from UCSC…
Exons
—
Transcript span
—
Strand
—
Variants mapped
—
Source
UCSC ncbiRefSeqCurated
All variants in HDAC4—Select a row to find it on the plot; use the link to open its page.
AF 1.1e-05 · 18 / 1,613,682 alleles · 0 hom · FAF 8.8e-06
Remaining individuals1 / 62,438
1.6e-05
European (non-Finnish)17 / 1,179,938
1.4e-05
0 alternate alleles recorded in 8 other groups: Admixed American, European (Finnish), Amish, East Asian, Middle Eastern, South Asian, Ashkenazi Jewish, African/African American.
gnomAD v2.1
AF 8e-06 · 2 / 249,630 alleles · 0 hom · FAF 3e-06
European (non-Finnish)2 / 112,718
1.8e-05
0 alternate alleles recorded in 7 other groups: African/African American, Admixed American, Ashkenazi Jewish, East Asian, European (Finnish), Remaining individuals, South Asian.
Statements
gnomAD v4.1
This variant is present in gnomAD v4.1 (AF= 1.11546e-05; MAF= 0.00112%, 18/1613682 alleles, homozygotes = 0) and has highest observed frequency in the Remaining individuals population (AF= 1.60159e-05; MAF= 0.00160%, 1/62438 alleles, homozygotes = 0); grpmax FAF= 8.78e-06.
gnomAD v2.1
This variant is present in gnomAD v2.1 (AF= 8.01186e-06; MAF= 0.00080%, 2/249630 alleles, homozygotes = 0) and has highest observed frequency in the European (non-Finnish) population (AF= 1.77434e-05; MAF= 0.00177%, 2/112718 alleles, homozygotes = 0); grpmax FAF= 2.95e-06.
gnomAD-Canada
Not available in gnomAD-Canada v1.0.
SpliceAI and Pangolin
SpliceAI acceptor lossat +45 bp
0.000
SpliceAI acceptor gainat +116 bp
0.001
SpliceAI donor lossat +128 bp
0.000
SpliceAI donor gainat -107 bp
0.000
Pangolin splice lossmagnitude shown
-0.003
Pangolin splice gain
0.004
Other predictors
REVEL
0.718
BayesDel
0.183
How the predictions were used
PP3SupportingACMG_2015Met at supporting strength: REVEL 0.718 meets the generic PP3 supporting threshold of >=0.644 for this missense variant.
Details ▾Hide ▴
Reasoning
The variant is a missense substitution, NM_001378414.1:c.1426C>T (p.Pro476Ser), so the generic PP3/BP4 missense path applies and REVEL is the sole applicable predictor; SpliceAI is not used for this path. REVEL is 0.718, which meets the published generic PP3 supporting threshold of >=0.644 from the ClinGen SVI REVEL calibration (Pejaver et al. 2022, PMID:36413997). BayesDel is not used because no generic ACMG-strength calibration is established.
Rule
Multiple lines of computational evidence support a deleterious effect on the gene or gene product (conservation, evolutionary, splicing impact, etc.).
Evidence considered
Variant consequence: missense, NM_001378414.1:c.1426C>T, NP_001365343.1:p.(Pro476Ser), in exon 12.
Applicable computational path: REVEL only for a missense variant; the SpliceAI result is not counted for PP3/BP4 on this path.
Local REVEL lookup: score 0.718.
ClinGen SVI REVEL calibration (Pejaver et al. 2022, Am J Hum Genet; PMID:36413997): generic PP3 supporting threshold >=0.644; REVEL 0.718 meets it.
BayesDel score 0.183125 is not used because no generic ACMG-strength calibration is established.
Sources
revel
BP4ACMG_2015Not met: REVEL 0.718 exceeds the generic BP4 supporting threshold of <=0.29, so the missense result is indeterminate for benign computational evidence.
Details ▾Hide ▴
Reasoning
The variant is a missense substitution, NM_001378414.1:c.1426C>T (p.Pro476Ser), so the generic BP4 missense path applies and REVEL is the sole applicable predictor; SpliceAI is not used for this path. REVEL is 0.718, which is above the generic BP4 supporting threshold of <=0.29 and therefore lies outside the benign-supporting range; the gray-zone REVEL result does not permit substituting the SpliceAI score. BayesDel is not used because no generic ACMG-strength calibration is established.
Rule
Multiple lines of computational evidence suggest no impact on gene or gene product (conservation, evolutionary, splicing impact, etc)
Evidence considered
Variant consequence: missense, NM_001378414.1:c.1426C>T, NP_001365343.1:p.(Pro476Ser), in exon 12.
Applicable computational path: REVEL only for a missense variant; the SpliceAI result is not counted for PP3/BP4 on this path.
Local REVEL lookup: score 0.718.
ClinGen SVI REVEL calibration (Pejaver et al. 2022, Am J Hum Genet; PMID:36413997): generic BP4 supporting threshold <=0.29; REVEL 0.718 does not meet it and is gray-zone for BP4.
BayesDel score 0.183125 is not used because no generic ACMG-strength calibration is established.
Sources
revel
BP7N/ANot applicable: BP7 requires a synonymous variant, and this is a missense variant.
Details ▾Hide ▴
Reasoning
BP7 (Richards et al. 2015, PMID:25741868) is defined for a synonymous (silent) variant for which splicing prediction algorithms predict no impact to the splice consensus sequence and the nucleotide is not highly conserved. NM_001378414.1:c.1426C>T in HDAC4 is a missense substitution predicted to produce NP_001365343.1:p.(Pro476Ser). As a result, the encoded protein sequence is altered, so the criterion's silent-variant premise does not hold regardless of any splicing prediction, so BP7's structural prerequisite is not met by this variant class. No VCEP criteria specification covers BP7 for HDAC4, so the generic ACMG/AMP 2015 definition applies. This determination was made deterministically from the variant's consequence class, prior to LLM adjudication.
Rule
deterministic_prefilter: requires_synonymous
Evidence considered
Deterministic consequence classification: missense (prefetch.json normalized protein consequence)
VCEP criterion policy: absent
Sources
generic_acmg_combination_rules
Statement
In silico
SpliceAI predicts no significant splice impact for this variant (max delta score = 0.00). REVEL score = 0.718. BayesDel score = 0.183125.
0 paper records listed. No publication is explicitly linked to an applied criterion in the recorded metadata.
Screenshots represent source records captured during evidence collection. Select one to view the recorded source content.
gnomAD v4.118 / 1,613,682 recorded allelesOpen source ↗
The evidence statements recorded by the interpretation pipeline. They have not been reinterpreted by the page.
gnomAD v4.1
This variant is present in gnomAD v4.1 (AF= 1.11546e-05; MAF= 0.00112%, 18/1613682 alleles, homozygotes = 0) and has highest observed frequency in the Remaining individuals population (AF= 1.60159e-05; MAF= 0.00160%, 1/62438 alleles, homozygotes = 0); grpmax FAF= 8.78e-06.
gnomAD v2.1
This variant is present in gnomAD v2.1 (AF= 8.01186e-06; MAF= 0.00080%, 2/249630 alleles, homozygotes = 0) and has highest observed frequency in the European (non-Finnish) population (AF= 1.77434e-05; MAF= 0.00177%, 2/112718 alleles, homozygotes = 0); grpmax FAF= 2.95e-06.
gnomAD-Canada
Not available in gnomAD-Canada v1.0.
ClinVar
This variant is absent from ClinVar.
In silico
SpliceAI predicts no significant splice impact for this variant (max delta score = 0.00). REVEL score = 0.718. BayesDel score = 0.183125.
Functional
OncoKB identified curated literature and non-variant-specific oncogenicity context for review; listed oncogenicity label: not classified.
Somatic
This variant does not lie in a statistically significant hotspot. This variant has not previously been reported in somatic cancers (COSMIC).
Cancer Hotspots
This variant does not lie in a statistically significant hotspot.
This variant was interpreted by pipeline 12.0.1.
The current version is 12.0.2.
Re-running queues a fresh interpretation; the result replaces this page when complete.
Re-runs are not free. Blank draws on today's public interpretation allowance; with a code, it uses one of that code's uses.